43 results
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
26 Mar 24
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
7:12am
; the impact of the COVID-19 pandemic on our business, supply chain and labor force; and the risks and uncertainties described in the “Risk Factors
424B5
CGTX
Cognition Therapeutics Inc
13 Mar 24
Prospectus supplement for primary offering
4:04pm
, the trading prices for biopharmaceutical companies have been highly volatile as a result of supply chain disruptions and the COVID-19 pandemic … and market conditions, including with respect to the financial markets in the United States and worldwide resulting from inflation, the COVID-19 pandemic
424B5
CGTX
Cognition Therapeutics Inc
11 Mar 24
Prospectus supplement for primary offering
4:06pm
for biopharmaceutical companies have been highly volatile as a result of supply chain disruptions and the COVID-19 pandemic. These factors include those in this “Risk … with respect to the financial markets in the United States and worldwide resulting from inflation, the COVID-19 pandemic and ongoing global and regional
424B4
CGTX
Cognition Therapeutics Inc
8 Jan 24
Prospectus supplement with pricing info
4:11pm
outbreaks of communicable diseases, including the COVID-19 pandemic, geopolitical turmoil, including the ongoing global and regional conflicts or increased
8-K
EX-99.1
sihz5m8ickqb5fbbm
4 Jan 24
Other Events
4:21pm
8-K
EX-99.1
hswmouk odz628ij9
2 Nov 23
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:41am
8-K
EX-99.1
4jx5zii
12 Sep 23
Other Events
7:00am
8-K
EX-99.1
d6jygef80a2w4x
24 Aug 23
Regulation FD Disclosure
7:00am
8-K
EX-99.1
duvfm6v mgjzq7zpd
8 Aug 23
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
7:05am
8-K
EX-99.1
5520 ad6noc
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
8-K
EX-99.2
h5tvndhzt6
28 Jun 23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
7:27am
8-K
EX-99.1
2v8pcy exlhek
4 May 23
Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4:06pm
8-K
EX-99.1
g3ufm8 5cu8j6ziv
19 Apr 23
Developing disease-modifying medicines for degenerative disorders Analyst Breakfast April 2023
7:30am
S-3
qcdfz5yj zne
23 Dec 22
Shelf registration
4:16pm
8-K
EX-99.1
uww2c7ae
16 Nov 22
Developing disease - modifying medicines for degenerative disorders November 2022
5:18pm